Sutro Biopharma (STRO) Change in Receivables (2017 - 2025)

Sutro Biopharma has reported Change in Receivables for 9 years, with the latest figure at $55000.0 in Q4 2025.

• Quarterly Change in Receivables fell 97.2% year-over-year to $55000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.6 million (up 83.11% YoY) and the FY2025 annual result came in at -$4.6 million, up 83.11% from the prior year.
• Change in Receivables rose to $55000.0 in Q4 2025 per STRO's latest filing, from -$4.1 million in the prior quarter.
• Over five years, Change in Receivables peaked at $86.0 million in Q2 2022 and troughed at -$86.4 million in Q3 2022.
• A 5-year average of -$79550.0 and a median of $125000.0 in 2021 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables surged 4348.27% in 2022, then sank 19425.4% in 2024.
• Over 5 years, Change in Receivables stood at $124000.0 in 2021, then slumped by 3429.03% to -$4.1 million in 2022, then jumped by 571.2% to $19.5 million in 2023, then slumped by 89.92% to $2.0 million in 2024, then plunged by 97.2% to $55000.0 in 2025.
• According to Business Quant data, Change in Receivables over the past three periods registered $55000.0, -$4.1 million, and -$5.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.